These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2583 related items for PubMed ID: 17950147

  • 1. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 2. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, Nuti R.
    Am Heart J; 2006 Dec 23; 152(6):1096.e9-15. PubMed ID: 17161060
    [Abstract] [Full Text] [Related]

  • 3. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P.
    J Am Coll Cardiol; 2008 Jan 15; 51(2):103-12. PubMed ID: 18191732
    [Abstract] [Full Text] [Related]

  • 4. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
    Comín-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J.
    J Card Fail; 2009 Nov 15; 15(9):727-35. PubMed ID: 19879457
    [Abstract] [Full Text] [Related]

  • 5. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI, Zueva EB, Silverberg DS, Shaked M.
    J Nephrol; 2008 Nov 15; 21(2):236-42. PubMed ID: 18446719
    [Abstract] [Full Text] [Related]

  • 6. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
    Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM.
    J Am Coll Cardiol; 2006 Sep 19; 48(6):1225-7. PubMed ID: 16979010
    [Abstract] [Full Text] [Related]

  • 7. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E.
    Cardiol J; 2009 Sep 19; 16(1):43-9. PubMed ID: 19130415
    [Abstract] [Full Text] [Related]

  • 8. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure.
    Conraads VM, Beckers P, Vaes J, Martin M, Van Hoof V, De Maeyer C, Possemiers N, Wuyts FL, Vrints CJ.
    Eur Heart J; 2004 Oct 19; 25(20):1797-805. PubMed ID: 15474694
    [Abstract] [Full Text] [Related]

  • 9. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC.
    Rev Port Cardiol; 2004 Dec 19; 23(12):1557-82. PubMed ID: 15732658
    [Abstract] [Full Text] [Related]

  • 10. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
    Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL.
    J Am Coll Cardiol; 2006 Jan 03; 47(1):91-7. PubMed ID: 16386670
    [Abstract] [Full Text] [Related]

  • 11. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 12. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, Nuti R.
    Am Heart J; 2007 Oct 13; 154(4):645.e9-15. PubMed ID: 17892986
    [Abstract] [Full Text] [Related]

  • 13. No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure.
    Nilsson BB, Westheim A, Risberg MA, Arnesen H, Seljeflot I.
    Scand Cardiovasc J; 2010 Aug 13; 44(4):223-9. PubMed ID: 20636229
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.
    Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N.
    J Card Fail; 2007 Feb 13; 13(1):14-7. PubMed ID: 17338998
    [Abstract] [Full Text] [Related]

  • 15. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C, Reinecke H, Stypmann J, Rothenburger M, Schmid C, Breithardt G, Wichter T, Gradaus R.
    J Heart Lung Transplant; 2006 Sep 13; 25(9):1135-41. PubMed ID: 16962477
    [Abstract] [Full Text] [Related]

  • 16. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics.
    Romeo R, Scalisi C, Tafuri L, Romeo A, Maugeri D, Sorace R.
    Arch Gerontol Geriatr; 2010 Sep 13; 50(1):101-4. PubMed ID: 19371958
    [Abstract] [Full Text] [Related]

  • 17. Changes in B-type natriuretic peptides after surgical ventricular restoration.
    Sartipy U, Albåge A, Larsson PT, Insulander P, Lindblom D.
    Eur J Cardiothorac Surg; 2007 May 13; 31(5):922-8. PubMed ID: 17321144
    [Abstract] [Full Text] [Related]

  • 18. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
    Schou M, Gustafsson F, Corell P, Kistorp CN, Kjaer A, Hildebrandt PR.
    Am Heart J; 2007 Jul 13; 154(1):123-9. PubMed ID: 17584564
    [Abstract] [Full Text] [Related]

  • 19. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N.
    J Med Assoc Thai; 2003 May 13; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [Abstract] [Full Text] [Related]

  • 20. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR, Zhang YH, Xu Q, Qiu HX, Chen Q.
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun 13; 11(6):429-32. PubMed ID: 19558803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 130.